Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say
ALNYAlnylam Pharmaceuticals(ALNY) Zacks Investment Research·2024-02-16 00:31

For the quarter ended December 2023, Alnylam Pharmaceuticals (ALNY) reported revenue of 439.72million,up31.2439.72 million, up 31.2% over the same period last year. EPS came in at -1.10, compared to -1.68intheyear−agoquarter.Thereportedrevenuerepresentsasurpriseof−1.311.68 in the year-ago quarter. The reported revenue represents a surprise of -1.31% over the Zacks Consensus Estimate of 445.57 million. With the consensus EPS estimate being -$1.20, the EPS surprise was +8.33%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they comp ...